Purpose: Telmisartan, an angiotensin II receptor blocker (ARB), also acts as an activator of peroxisome proliferator-activated receptor-gamma (PPAR-gamma; PPAR-γ). Several studies have explored the PPAR-γ-endothelial nitric oxide synthase (eNOS) pathway associated with improvement of endothelial function by telmisartan. e ability of telmisartan to induce gene expression and protein level of eNOS and PPARγ in adipocytes was investigated.
Age-related chronic pathologies such as atherosclerosis, diabetes and chronic kidney diseases are linked to oxidative stress [1, 2] . Oxidative stress alters many endothelium functions associated with traditional risk factors, triggering early vascular in ammation and a predisposition to atherosclerosis. e antihypertensive drugs currently in use were designed to decrease blood pressure, but not to cope with disorders in the metabolism of carbohydrates and lipids. Combinations of these disorders are usually found in hypertensive patients, which increase the risk of these patients developing cardiovascular disease and diabetes. Nonetheless, some of these drugs, such as angiotensin type 1 receptor (AT1R) blockers (ARBs), have been linked to a decrease in oxidative stress [3] and dyslipidemia as well as to a decrease in insulin resistance. Several clinical studies report that ARBs, such as telmisartan, prevent the onset of type 2 diabetes mellitus [4] , can prevent weight gain and obesity and can be bene cial in obesity-hypertension treatment [5] .
Adipose tissue plays an important role in regulating body metabolism [6] . e identi cation of regulators of adipogenesis raises the prospect of preventing or reversing obesity and its secondary e ects, including oxidative stress or insulin resistance, through pharmacological means. Increased oxidative stress causes insulin resistance by reducing insulin-stimulated glucose transport [7, 8] .
Endothelial nitric oxide synthase (eNOS) is activated through shear stress and diverse cellular events such as increased intracellular calcium or interactions with substrate and co-factors. eNOS regulation involves multiple levels of transcriptional, translational and post-translational regulation [1, 9] . e latter controls lipid modi cations, phosphorylation events and interactions with protein partners such as calmodulin, caveolin-3 and AT1 receptors [10] . eNOS activity is increased by phosphorylation of serine (Ser) at residues 1177, 633 and 615. Ser 1177 constitutes the most important eNOS phosphorylation regulation site and is associated with eNOS activity in response to numerous stimuli. A number of kinases are implicated in Ser 1177 phosphorylation [11] , turning the eNOS synthesis regulation into a complex process. Factors such as blood ow-induced phosphatidyl inositol 3-kinase, Akt-activation and eNOS-Ser 1177 phosphorylation cascade result in reduced calcium dependence and a sustained release of endothelial nitric oxide (NO). In contrast, the phosphorylation of threonine at residue 495 ( r 495 ) acts as a negative regulator for eNOS activity [12, 13] . Agonists of NO synthesis induce dephosphorylation of r 495 in the Ca 2+ / Calmodulin binding domain, increasing eNOS activity. In contrast, it has been show that Protein Kinase C (PKC) phosphorylates eNOS-r 495 , although the speci c isoform of PKC responsible is unknown [13] . In addition, experiments with mutants r 495 Ala, mimicking r 495 dephosphorylation, show the importance of r 495 cannot be explained by regulating the calmodulin binding domain [14] .
In this study, we evaluated the telmisartan-derived antioxidant properties in 3T3-L1 cells di erentiated to adipocytes, and whether these properties were related to di erences in eNOS gene expression or protein phosphorylation. e relationship between these properties and PPAR-γ activity were also evaluated.
Materials and Methods

Adipocyte di erentiation assay
Mouse 3T3-L1 pre-adipocytes were maintained in DMEM supplemented with 10% heat-inactivated FBS and antibiotics in a 5% CO 2 atmosphere at 37ºC. Sub-con uent cells cultured in 60 mm dishes were maintained in DMEM medium or differentiation medium using a standard di erentiation mixture as previously described [15, 16] (1 µM dexamethasone, 0.5 mM 3-isobutyl-1-methylxanthine (IBMX), 10 µg/ml insulin and 20% FBS). e rst pre-adipocyte group was exposed to vehicle (0.01% DMSO) and constituted the non-di erentiated control group ("control"). e second pre-adipocytes group was di erentiated to adipocytes and exposed to vehicle, and is considered as a control for di erentiation and maturation ("differentiated"). e third and fourth groups of pre-adipocytes were di erentiated to mature adipocytes, switched to normal medium and exposed to telmisartan. Time-response experiments were done exposing cells to telmisartan (5·10 -6 mol/L) [17] or vehicle (DMSO) for six or 12 hours.
uantization of intracytoplasmic lipids
Cells were xed by the addition of 10% formalin. A er at least 5 min at RT, the xation solution was replaced by 60% isopropyl alcohol and then cells were stained with Oil Red solution (Sigma O-0625) [18] . e extracted dye was spectrophotometrically quanti ed at 520 nm. Lipid accumulation was compared between cells exposed or not to telmisartan.
Reactive Oxygen Species (ROS) production in adipocytes
ROS production was measured by the lucigenin-derived chemiluminescence (LDCL) method. Lucigenin is widely used as a chemiluminescent detector of the superoxide anion radical in vitro enzymatic systems and intact cells [19] . Con uent cells in 60 mm dishes were harvested in trypsin, centrifuged and resuspended in 900 µl Kreb´s bu er, and 250 µM lucigenin was added. e reaction was monitored with Berthold Sirius luminometer over the course of 10 min.
Determination of nitrite/nitrate
Nitrite and nitrate concentrations were determined in cell culture supernatants using the NO quantization kit (Promega). First, the samples were deproteinizated; culture medium samples (400 µl) were mixed with 800 µl of trichloroacetic acid (TCA) and centrifuged at 8000 rpm for 20 minutes at 4ºC. e supernatant was used for determination of nitrite and all measurements were done in triplicate. A nitrite standard reference curve was prepared with nitrite stock solution and distillated water. Aliquots ( 50 µl) of each experimental sample were incubated with sulfanilamide for 10 minutes, before adding a NED (N-1-napthylethylenediamine dihydrochloride) solution. A er 10 minutes, the absorbance was measured at 540 nm.
Gene expression assays
Expression levels of PPARγ, adipocyte protein (aP2), eNOS and the products of inducible Nitric Oxide (iNOS) genes were determined by real-time polymerase chain reaction (RT-PCR) ampli cation. Total RNA was isolated with PureZOL (BioRad) and cDNA synthesized using iScript (Bio-Rad) according to manufacturer instructions. PCR reactions were performed in a CFX 96 (BioRad) device. Samples were measured in triplicate and the ΔΔCt method was used for quanti cation a er normalizing the Ct of each sample to the Ct obtained for the ampli cation of a 223 bp fragment of the glyceraldehyde phosphate dehydrogenase (GAPDH) gene. Primer speci city was con rmed by melting point analysis for each primer pair as well as by using standard agarose electrophoresis.
Western blot
Cells grown under the described conditions were lysed in a bu er containing 6 M urea, 25% glycerol, 0.1% SDS, 0.5% sodium deoxycholic acid, 1% Nonidet P-40 substitute (Sigma), 150 mM NaCl, 50 mM Tris/HCl (pH 7.8) and a protease inhibitor mixture (Roche) [20] . e protein concentration of the lysate was determined using the Bradford method (BioRad).
en, 20 µg samples of protein in Leamli bu er were denatured for 5 min at 95ºC and subjected to sodium dodecyl sulfate (SDS)-polyacrylamide gels electrophoresis (PAGE) on 5-7.5% polyacrilamide gels.
e transfer was carried out on Polyvinylidene uoride (PVDF) membranes that were blocked with 5% non-fat milk overnight and incubated with the following primary antibodies: β-actin (sc47778), PPARγ (sc-7196), eNOS native (ab51086), p-NOS3-Ser1177 (sc21871) and p-NOS3-r495 (sc19827) (Santa Cruz Biotechnology) for 1 h. A er a wash, the membranes were incubated with the appropriate secondary antibody (sc2030 and sc2005) for 1 h. e protein bands were detected with an ECL system (Amersham Pharmacia Biotech). e membranes were stripped and re-hybridized with another antibody. Densitrometric analyses of inmunoblots were performed using the ImageJ free so ware (http://rsb.info.nih.gov/ij/). Results were normalized using β-actin as the control.
Statistical Analysis
Data are expressed as mean ± SEM. Statistical signi cance of di erences between mean values was evaluated by using the Mann-Whitney test. Two-sides P values <0.05 were considered to indicate statistical signi cance.
Results
Telmisartan induces slightly aP2 gene expression
To evaluate 3T3-L1 cells di erentiation, the expression of aP2 was measured [21, 22] . e relative expression of aP2 gene was signi cantly higher in adipocytes than pre-adipocytes ( Figure  1 ). When switched to telmisartan, a slightly but signi cant increase in aP2 relative gene expression was also observed. 
Telmisartan reduces ROS production in adipocyte cells
To assess the involvement of oxidative stress in adipocyte differentiation, ROS production was evaluated. ROS production was markedly increased during di erentiation of 3T3-L1 cells into adipocytes. As depicted in Figure 2 , once di erentiated, switched to non-di erentiation medium and treated with telmisartan at indicated time-points, a signi cant reduction in ROS production was observed (p =0.0286).
Nitric oxide metabolites and telmisartan treatment
In order to assess oxidative stress in adipocyte cells exposed to telmisartan, the production of nitrates and nitrites in the culture cell supernatants were measured. e results showed no statistically signi cant di erences between any of groups (Figure 3) . erefore, there was no clear correlation between NO metabolites production and either cell di erentiation or treatment.
Nitric oxide gene expression increases during di erentiation process
Nitric oxide has been reported as an important mediator of adipocyte physiology with lipogenic properties [23] . For this reason, the relative expression of eNOS and iNOS genes between groups was measured. In cells exposed to telmisartan for 6 or 12 h, the relative expression of eNOS and iNOS were statistically diminished with respect to untreated adipocytes (*p = 0.0078 and **p = 0.0208, respectively) ( Figure 4) . Consistent with previous ndings [23] , no signi cant di erences in the eNOS and iNOS gene expression in treated cells with respect to pre-adipocytes were observed.
E ect of telmisartan on eNOS native and phosphorylated forms
Since the relationship among the mRNA transcription, protein translation and eNOS activity is far from a simple one, we then explored whether these subtle changes in eNOS gene expression correlated with native and phosphorylated eNOS protein forms. No di erences in native eNOS protein expression between pre-adipocytes, adipocytes and adipocytes exposed to telmisartan were observed (Figure 5a) . us, analysis of the eNOS expression data and the native protein argue for the role of other transcriptional regulators to explain the increased oxidative stress observed in adipocytes with respect to pre-adipocytes as well as the signi cant decrease that was observed in cells treated with telmisartan. To evaluate this, the phosphorylation status of serine and threonine at positions 1177 and 495, respectively, were measured. As depicted in Figure 5b , signi cant increases in the phosphorylation of Ser 1177 residue in adipocytes exposed to telmisartan were seen at 6 h (p = 0.0002) and 12 h (p = 0.0224), in comparison with preadipocytes ("control"). Notably, eNOS-Ser 1177 phosphorylation was signi cantly increased at 6 h in comparison with the untreated adipocytes group ("di erentiated") (p = 0.0119) but the increase seen by 12 h was not signi cant. Interestingly, a di erent pattern was seen for r 495 , where the phosphorylation level was increased in untreated adipocytes in comparison with pre-adipocytes (p = 0.0002) and adipocytes exposed for 6 h (p = 0.02) (Figure 5c ). In addition, a statistically signi cant di erence was observed between pre-adipocytes and telmisartan-treated cells at both 6 h (p = 0.0007) and 12 h in comparison with pre-adipocytes (p = 0.0003). Finally, eNOSr 495 phosphorylation was signi cantly higher in cells exposed to telmisartan for 12 h in comparison with those exposed for only 6 h (p = 0.03).
Telmisartan preserves PPARγ gene expression
To determine whether the antioxidant e ects of telmisartan depend on PPARγ, PPARγ gene expression was compared in pre-adipocytes, untreated adipocytes and adipocyte treated with telmisartan [17] . As depicted in Figure 6a , a signi cant increase in the PPARγ relative gene expression was seen in comparison with untreated adipocytes (di erentiated) with respect to pre-adipocytes group (control) (p = 0.0003). In contrast, a signi cant decrease in the PPARγ relative gene expression was observed for telmisartan-exposed adipocytes, for both 6 h and 12 h, in comparison with non-exposed adipocytes (p = 0.0064 and p = 0.0001, respectively). A er 12 h of telmisartan exposure PPARγ relative gene expression was lower than that obtained at 6 h (p = 0.0002).
Telmisartan preserves PPARγ protein levels
PPARγ protein levels were analysed by Western blot analysis.
e results show no signi cant di erences between treated and pre-adipocyte (control) groups, or between untreated and telmisartan-treated adipocytes a er 6 h (p = 0.06), (Figure 6b) .
Discussion
e results obtained in the present study support the partial independence of the PPARγ-eNOS pathway to explain some of the antioxidant properties that have been attributed to telmisartan. Following telmisartan treatment, a timedependent decrease of the PPARγ gene transcription levels occurred in adipocytes, reaching its lowest level at 12 hours of treatment. In contrast, six hours a er telmisartan exposure, the maximum levels of eNOS protein phosphorylation at Ser 1177 were observed, whereas r 495 phosphorylation at Ser 1177 diminished and phosphorylation at the inactivating r 495 residue increased; both changes were statistically signi cant. e telmisartan activity through PPARγ pathway has been reported widely in several models, tissues and conditions [24] [25] [26] [27] , as well as the stimulation of eNOS by telmisartan through a PPARγ and Rho-kinase pathway [28, 29] . As is known, adipocyte di erentiation activates the transcription factor CCAAT/enhancer-binding protein β (C/EBPβ) [30] , which subsequently stimulates PPARγ expression, insulin or insulin-like growth factor-1, promoting adipocyte di erentiation. Following di erentiation, PI3-kinase and Akt are activated [31] and, in a similar way to eNOS phosphorylation at Ser 1177 , promote an increase in eNOS activity and NO bioavailability. Along with this, it has been shown that telmisartan also induces kinase activation to increase in Ser 1177 whereas r 495 phosphorylation status is unknown [32] .
Interestingly, the di erentiation of 3T3 cells has been associated with increased oxidative stress, which reduces NO bioa- Representative images of Western blot and graphed densitometric analysis (%) of (a) native and phosphorylated at (b) Ser1177 and (c) r495 eNOS protein levels in the four experimental groups (from le to right of the images are two samples of cell lysates from pre-adipocytes, untreated adipocytes and adipocytes exposed to telmisartan for 6 and 12 hours respectively). Native eNOS (a) remained unchanged in all experimental groups. Phosphorylation at Ser1177 (b) increased signi cantly a er 6 h of telmisartan exposure with respect to pre-adipocytes (p*= 0.0002) and to non-treated adipocytes (p** = 0.0119). e di erence between pre-adipocytes and cells exposed to telmisartan for 12h was also signi cant (p***= 0.0224). Interestingly, phosphorylation of r495 (c) decreased at 6h with respect to pre-adipocytes (p*= 0.0007) and untreated adipocytes (p** = 0.02).
vailability. NO metabolites were also analysed in this study in all four cell groups, but the results were inconclusive as it was not possible to discriminate the source of NO production Several studies have shown that oxidative stress induces a compensatory increase in PPARγ gene transcription, which is thought to occur because of a loss of PPARγ activity. In our work, a compensatory increase in PPARγ gene expression was observed in adipocytes in comparison with pre-adipocytes and treated adipocytes. Furthermore, the activity of PPARγ can be nely tuned through integration of diverse phosphorylation events [33, 34] . In this regard, a downward trend in PPARγ protein levels in cells treated with telmisartan for 6 hours in comparison with the untreated group. e antioxidant properties of telmisartan are related to several phosphorylation sites of eNOS [35] .
e current knowledge of eNOS phosphorylation implicates a complex group of phosphorylation sites at Ser 1177 , Ser 114 , Ser 615 , Ser 633 and r 495 , with resultant e ects on eNOS enzyme activity. PI3-kinase and Akt induce eNOS phosphorylation [31] at Ser 1177 , increasing eNOS activity. e eNOS-Ser 1177 phosphorylation has been associated with administration of PPARγ agonists [36] , insulin [37] , bradykinin [38] , Akt/PKB (protein kinase B) or AMPK(AMP-activated protein kinase) [39, 40] , these latter molecules also involved in the PPARγ pathway. iazolidinediones are agonists of PPARγ and decrease serum triglycerides and fatty acids, resulting in glucose and insulin imbalance [41] , whereas telmisartan, a partial agonist of PPARγ, improves insulin sensitivity in adipose tissue [42] .
us, this action of telmisartan is not dependent on PPARγ activity.
On the other hand, the selective inhibition of endothelial PKC-β mediates the production of NO, and thus PKC, which phosphorylates eNOS-r 495 , leading to inhibition of the eNOS activity. As we commented before, Saitoh et al. [35] reported that telmisartan treatment decreased PKC activity and improved oxidative stress. Payne et al. [43] showed that peri-adventitial adipose-derived factors impair coronary endothelial NO production via a PKC-β-dependent, site-speci c phosphorylation of eNOS at r 495 . In this sense, our Western blot analysis revealed a greater increase in eNOS phosphorylation at the inhibitory residue r 495 in untreated murine adipocytes that was higher than that seen in the telmisartantreated group. Knorr et al. [9] reported that the phosphorylation of eNOS-Ser 1177 is a critical requirement for eNOS activation, but Mount et al. [11] suggested that the dephosphorylation of r 495 is a prerequisite for the phosphorylation of Ser 1177 . Fleming et al. [13] suggested that the dual phosphorylation/dephosphorylation of Ser 1177 and r 495 determines the eNOS activity, being dephosphorylation of r 495 previous to phosphorylation of Ser 1177 . Lin et al. [14] suggested that phosphorylation/dephosphorylation of r 495 may be an intrinsic switch mechanism to determinate NO in cells. Harris et al. suggest that phosphorylation of r 495 is enough to activate eNOS enzyme activity [12] . In our experiments, -Ser 1177 phosphorylation increased and eNOS-r 495 phosphorylation decreased with telmisartan treatment. Interestingly, this increased phosphorylation is not accompanied by increased PPARγ expression.
Taking together, these ndings are consistent with a telmisartan mechanism partially independent of PPARγ. We can only speculate as to the mechanisms by which telmisartan reduces oxidative stress. It might be possible that telmisartan inhibits activation of PKC, leading to dephosphorylation of r 495 and, consequently, to phosphorylation of Ser 1177 , which increases eNOS activity, thereby improving the oxidative state.
Conclusion
e present study gives experimental evidence that telmisartan treatment improves oxidative stress status in adipocytes. Our data point toward a previously unrecognized role of telmisartan in phosphorylation of eNOS-r 495 , which may be relevant for antioxidant properties of telmisartan. More studies are now needed to clarify this mechanism.
